Anticancer Therapies – News and Features

St. Jude researchers have treated tumors with genetically modified cells that sought out and activated a chemotherapy drug placed directly at the cancer cells.

The mutations involving single chemical bases in a gene, not affecting the protein sequence of the gene product, can alter the protein's drug binding ability.

Vanderbilt University Medical Center and the National Foundation for Cancer Research have established a cancer research center from $1 million funded by NFCR.

Researchers found that the more T-regulatory cells and the fewer T-cell lymphocytes present in the tumors of treated patients, the greater the likelihood the cancer would recur.

Ipsogen and a group of cancer centres lead by Institut Paoli-Calmettes have initiated the clinical trial for managing chemotherapeutic options in breast cancer.

The molecule, called SSEA-4, found on the surface of certain stem cells in bone marrow can give rise to fat, cartilage and bone.

The license agreement reinforces Geneservice's position as the provider of biological and genomic resources to life science researchers worldwide.

The Burnham will receive access to novel HuCAL GOLD-based research antibodies.

The trial will evaluate the effects of Imprime PGG™ in combination with G-CSF for mobilization of bone marrow stem cells into the peripheral blood.

The combination of two experimental drugs provides the synergistic action against acute myeloid leukemia cells.